Andrew L. Salzman, M.D., Chief Executive Officer

Dr. Salzman is a physician, scientist, inventor, and biomedical entrepreneur. Dr. Salzman founded and built Inotek Pharmaceuticals, a 140-person biotech company that raised $92M in venture capital and concluded a $600M license with Genentech. As CEO of Inotek, Dr. Salzman brought numerous new chemical entities from conception to clinical stage testing, including a treatment for glaucoma that demonstrated clinical proof of concept in late Phase 2 clinical trials.

Dr. Salzman has been funded by the U.S. National Institutes of Health (“NIH”), authoring 75 federal grants and receiving $164 million in federal grant and contract funding, $129 million in venture capital investment, and $27 million in strategic licensing and research support.

Dr. Salzman received an undergraduate degree from Yale College, a degree in medicine from Harvard Medical School, and completed a pediatric internship and residency at Columbia University Medical Center. He completed post-doctoral fellowships in pediatric infectious disease, neonatology, pediatric critical care, and mucosal immunology at the Weizmann Institute of Science in Rehovot (Israel), Boston Children’s Hospital Medical Center, Beth Israel Medical Center, and Massachusetts General Hospital.

Dr. Salzman serves as Founder and Chairman of Radikal Therapeutics, Salzman Capital Ventures, Salzman Lovelace Investments, Tisbury Pharmaceuticals, and Respirometics, and is the Director of Drug Development at the Lovelace Respiratory Research Institute.

Robert Farrell, J.D., President, COO and CFO

Mr. Farrell has more than 25 years of experience in the pharmaceutical, biotechnology, and medical device sectors. Mr. Farrell has had primary or significant responsibility for the completion of mergers & acquisitions, corporate partnerships, licensing transactions, and divestitures in both the U.S. and Europe. In addition, Mr. Farrell has many years of operational experience, including executive responsibility and responsibility for all financial operations.

Mr. Farrell has held senior positions with publicly listed companies, including Titan Pharmaceuticals, where he served as President and CEO from 2008 to 2009 and as Chief Financial Officer from 1996 to 2008. Mr. Farrell raised over $390M while at Titan via public equity and non-dilutive financings, including seven corporate partnerships. Previously, Mr. Farrell served as CFO, Corporate Group Vice President and General Counsel at Fresenius USA and Fresenius Medical Care, where he completed six corporate partnerships and M&A transactions totaling over $4B. Mr. Farrell received a law degree (J.D.) from the University of California’s Hastings College of Law and is a member of the California State Bar.

Dr. Sari Prutchi Sagiv, Vice President of Scientific Operations

Dr. Prutchi Sagiv has over 15 years of experience in various aspects of pharmaceutical development including: discovery, regulatory affairs, intellectual property, business development, clinical trials, and marketing. Dr. Prutchi Sagiv has lead the Scientific Operations in multiple cannabis-based drugs companies including Talent Biotech and BOL Pharma. She serves as Director of Tech Transfer at Mor Research Applications (Clalit Health Services commercializing arm), where she is responsible for raising capital via strategic partnerships for early stage technologies. Dr. Prutchi Sagiv holds an M.Sc. in Human Genetics and a Ph.D. in Cell Biology and Immunology from Tel Aviv University. In addition, she studied Business Administration at the Recanati School of Business at Tel Aviv University.

Ronen Raviv, Director of Finance

Mr. Raviv obtained his Bachelor degree in Business with concentration in accounting in 2006 from San Francisco State University. Upon graduating, he joined the EY San Francisco Office, where he carried out audits of private and public companies in the Silicon Valley, among them Oracle Corporation (Ticker: ORCL) and salesforce.com (Ticker: SFDC). In 2008 Mr. Raviv relocated to the Tel Aviv office of EY, where he worked primarily with clients in the technology and defense industries. Mr. Raviv’s main client at EY was Elbit Systems Ltd. (Ticker: ESLT), the largest publicly owned defense contractor in Israel, with subsidiaries operating in multiple countries under different governmental and private contracts, among them contracts with US government. Mr. Raviv led over 15 audit teams engaged in the global audit of Elbit Systems Ltd and its subsidiaries. In his last position, as Corporate Controller of DarioHealth Corp. (Nasdaq: DRIO), Mr. Raviv facilitated the company’s up-listing process to the Nasdaq in March 2016.Mr. Raviv joined as our Director of Finance in January of 2017 to oversee  the company’s global finance organization. His deep understanding of multi-national global organizations and extensive experience with executive teams, provide him with the leadership and insight that make him an integral part of our team.

Moshe Yeshurun, M.D., Senior Clinical Scientist

Dr. Moshe Yeshurun is Head of the Bone Marrow Transplantation Unit at the Rabin Medical Center, Petah-Tikva Israel.

Dr. Yeshurun received his M.D   degree from Tel Aviv University Sackler School of Medicine with distinction  in 1990 and his board certification in Internal Medicine and Hematology in 1996 and 2002, respectively.  Between the years 1998-2000 Dr. Yeshurun had his fellowship in bone marrow transplantation at Saint-Antoine and Saint-Louis hospitals in Paris, France.  In 2007 he established the Bone Marrow Transplantation Unit at the Davidoff Cancer Center, Rabin Medical Center and headed it since.

Between the years 2014-2017 he was committee member of the Israeli Society of Hematology and Transfusion Medicine.

His primary field of interest and research focus is graft-versus-host disease after allogeneic hematopoietic cell transplantation. He conducted several innovative clinical studies aiming to explore the role of cannabidiol in the prevention and treatment of graft-versus-host disease and is the PI of several prospective   investigator-initiated multicenter clinical trials.